MGI PHARMA, Inc. (Nasdaq:MOGN), today announced that it has begun sales and marketing of the Salagen (R) 7.5 mg tablet (pilocarpine hydrochloride) in the United States. The Federal Drug Administration (FDA) approved the Salagen 7.5 mg tablet as an alternative strength to the currently marketed Salagen 5 mg tablet. Salagen tablets are indicated for the treatment of symptoms of dry mouth from salivary gland hypofunction
caused by radiotherapy for cancer of the head and neck. It is also
indicated in the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.
"The introduction of a higher strength Salagen tablet will offer
more dosing flexibility for clinicians and head and neck cancer
patients suffering from radiation therapy induced dry mouth," said
Lonnie Moulder, president and chief executive officer of MGI PHARMA. "The higher strength tablet allows healthcare providers to adjust the dosing schedule according to the individual needs of the patient.
